



MALVERN, PENNSYLVANIA, AND STAFFORD, UK, December 10, 2007 — [PuriCore](#) (LSE: PURI), the life sciences company focused on the development and commercialization of its novel, safe antimicrobial technology, today announced that the US Patent and Trademark Office has granted PuriCore an additional patent for its Sterilox Systems. The new patent, US Patent No. 7,303,660, is part of the same patent family as PuriCore's previously issued US Patent No. 6,632,347, which covers an optimal process for operating PuriCore's Systems to prepare its disinfection solutions.

PuriCore's technology is marketed currently in the US and UK as Sterilox Food Safety Systems and Sterilox Endoscopy Systems, respectively. These Sterilox Systems produce hypochlorous acid at near neutral pH, the same safe and effective antimicrobial solution produced by the human body to fight infection. Leading US supermarket retailers and UK hospitals use PuriCore's Sterilox Systems to control the spread of infectious pathogens.

"Together, these patents protect PuriCore's core technology and further verify its standing as a leader and innovator in the field of infection control," said Greg Bosch, CEO of PuriCore. "We continue to expand our broad intellectual property portfolio focused on safe and effective antimicrobial solutions and devices for producing these solutions."

About PuriCore

[PuriCore](#) (London Stock Exchange: PURI) is a life sciences company focused on developing and commercializing proprietary products that safely, effectively, and naturally kill contagious pathogens. PuriCore's technology provides a solution to a broad range of markets that depend upon controlling contamination, including food safety, medical device disinfection, wound therapy, and hospitality. The Company's proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores.

Deploying hypochlorous acid solutions as soaks, sprays, mists, and in other forms, PuriCore's technology is designed to limit the spread of infectious disease, including major public health threats of *M. tuberculosis*, *MRSA*, *E.coli*, norovirus, avian influenza, HIV, polio virus, *Helicobacter pylori*, and *Legionella*. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK.

To receive additional information on PuriCore, please visit our web site at www.puricore.com, which does not form part of this press release.

Contacts:

Jennifer Guinan
Sage Strategic Marketing
610-410-8111
jennifer@sagestrat.com

Greg Bosch, CEO
Keith Goldan, CFO
PuriCore
484 321 2700